Recent Updates
Recently added Catalysts

oxycodone IR

Phase 3

Back Pain | Small molecule | Pain |Johnson & Johnson|Last Updated: May 9, 2014

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment108

FDA Designations

No designations recorded

Clinical trial landscape

oxycodone IR · 2 trials · 4 indications

Phase 3 2
NCT00784277A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint DiseaseJoint Diseases
COMPLETED597 Analytics
NCT00771758Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With OsteoporosisBack Pain
COMPLETED108 Analytics
PHASE3COMPLETED
A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease
Joint DiseasesUnlock trial analytics
PHASE3COMPLETED
Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis
Back PainUnlock trial analytics

Study Endpoints

Primary Endpoints

5-Day Sum of Pain Intensity Difference (SPID5)
Day 1 to Day 5

SPID5 was calculated as the weighted (weights is taken as the number of hours elapsed since the previous measurement) sum of the PID collected up to 5 days. Pain intensity (PI) score is calculated as the average PI over the past 12 hours using an 11-point (0 to 10) numerical rating scale (NRS) where "0" is no pain and "10" is pain as bad as you can imagine. The difference between baseline PI at the qualifying period and current PI is pain intensity difference (PID).

Spontaneous Bowel Movements Per Week (SBMs/Week)
Week 1 to Week 2

The number of SBM over the 14-day IR treatment phase was determined from the Bowel Function Patient Diary and factored to enable a per week value to be used. An SBM is defined as any BM that has occurred without the use of a laxative, enema, suppository, or manual manipulation within the previous 24 hours.

Sum of Pain Intensity Difference Over 3 Days (SPID72)
3 Days (72 hours)

Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID72 was calculated as the time-weighted Sum of PID scores over 72 hours. The range of SPID72 is from -720 to 720. The higher value in SPID indicates greater pain relief. The study was terminated prematurely due to slow enrollment after 108 of 600 subjects enrolled. Valid statistical conclusions cannot be made due to the low number of subjects.

Secondary Endpoints

30% Responder Rate on Day 3.
Day 3
50% Responder Rate on Day 3.
Day 3
30% Responder Rate on Day 5.
Day 5
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
001EXPERIMENTALTapentadol IR (CG5503) 50mg for 14 days
002EXPERIMENTALTapentadol IR (CG5503) 75mg for 14 days
003ACTIVE_COMPARATORoxycodone IR 10mg for 14 days
004PLACEBO_COMPARATORplacebo 1 capsule for 14 days
005EXPERIMENTALTapentadol ER (CG5503) flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
006ACTIVE_COMPARATORoxycodone CR flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
007PLACEBO_COMPARATORplacebo Tablets and capsules 2 x a day for 28 days

Interventions

NameTypeDescription
oxycodone CRDRUGflexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
oxycodone IRDRUG10mg for 14 days
Tapentadol ER (CG5503)DRUGflexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
Tapentadol IR (CG5503)DRUG50mg for 14 days
placeboDRUG1 capsule for 14 days
tapentadol IRDRUG50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 80 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * A clinical diagnosis of osteoarthritis of the hip or knee * End-stage degenerative joint disease * Eligibility for primary unilateral total or partial joint replacement surgery * Pain level moderate to severe and at such a level as to require daily doses of an opioid analgesic...

Countries:United States
Unlock Eligibility Criteria